The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicopathological features and response to platinum-based chemotherapy in pancreatic neuroendocrine carcinoma: A retrospective multicenter study of 70 patients.
 
Susumu Hijioka
Honoraria - Eisai; Nobelpharma; Novartis; Pfizer; Takeda
Research Funding - Teijin Pharma (Inst)
 
Waki Hosoda
No Relationships to Disclose
 
Keitaro Matsuo
No Relationships to Disclose
 
Makoto Ueno
Honoraria - Abbott Japan; AstraZeneca; Boston Scientific; Kyowa Hakko Kirin; Lilly; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - Daiichi Sankyo (Inst); Merck Serono (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Masayuki Furukawa
No Relationships to Disclose
 
Hideyuki Yoshitomi
Speakers' Bureau - Astellas Pharma; Lilly Japan; Taiho Pharmaceutical
 
Noritoshi Kobayashi
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Ako City Hospital; Taiwan Digestive Disease Week; The Tokyo Cooperative Oncology Group; Tokyo Medical University Hachioji Medical Center
Consulting or Advisory Role - Bayer Yakuhin; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; NanoCarrier
Speakers' Bureau - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Guerbet; Kowa; Kyowa Hakko Kirin; Lilly Japan; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Tetsuhide Ito
No Relationships to Disclose
 
Shoji Nakamori
Research Funding - Eisai (Inst)
 
Hiroshi Ishii
Honoraria - Ajinomoto; Bayer; Daiichi Sankyo; Hospira; Kyowa Hakko Kirin; Lilly; Mochida Pharmaceutical Co. Ltd.; Nobelpharma; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Torii Pharmaceutical (Inst)
 
Yuzo Kodama
No Relationships to Disclose
 
Chigusa Morizane
Honoraria - Lilly; Novartis; Pfizer; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Novartis; Yakult Honsha
Research Funding - GlaxoSmithKline (Inst); Nobelpharma (Inst); Pfizer (Inst)
 
Hiroaki Yanagimoto
No Relationships to Disclose
 
Kei Yane
No Relationships to Disclose
 
Kenji Notohara
No Relationships to Disclose
 
Junji Furuse
Honoraria - Ajinomoto; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Meiji Seika Kaisha; Merck Serono; Mitsubishi Tanabe Pharma; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Sawai Pharmaceutical Co; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical; Zeria Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hisamitsu Pharmaceutical (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Kayaku (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Yasushi Yatabe
No Relationships to Disclose
 
Nobumasa Mizuno
Honoraria - Kyowa Hakko Kirin; Lilly; Novartis; OncoTherapy Science; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha